Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
revised:
01
03
2024
received:
27
11
2023
accepted:
02
04
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
In the context of T-cell replete haploidentical stem cell transplantation (Haplo-SCT) using post-transplantation cyclophosphamide (PT-Cy), it is still unknown whether peripheral blood (PB) or bone marrow (BM) is the best graft source. While PB is associated with a higher incidence of graft-versus-host disease (GVHD), it may induce a stronger graft-versus-leukemia effect compared to BM, notably in acute myeloid leukemia (AML). From the EBMT registry database, we compared T-cell replete PB (n = 595) versus BM (n = 209) grafts in a large cohort of 804 patients over the age of 60 years who underwent Haplo-SCT with PT-Cy for an AML in first or second complete remission. The risk of acute GVHD was significantly higher in the PB group (Grade II-IV: HR = 1.67, 95% CI [1.10-2.54], p = 0.01; Grade III-IV: HR = 2.29, 95% CI [1.16-4.54], p = 0.02). No significant difference was observed in chronic GVHD or non-relapse mortality. In the PB group, the risk of relapse was significantly lower in the PB group (HR = 0.65, 95% CI [0.45-0.94], p = 0.02) and leukemia-free survival was significantly better (HR = 0.76, 95% CI [0.59-0.99], p = 0.04), with a trend toward better overall survival (HR = 0.78, 95% CI [0.60-1.01], p = 0.06). We conclude that in the specific context of Haplo-SCT with PT-Cy, PB grafts represent a valid option to decrease the risk of relapse and improve outcome of older AML patients who usually do not benefit from conditioning intensification.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Luznik L, O'Donnell PV, Symons HJ, et al. HLA‐haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high‐dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641‐650. doi:10.1016/j.bbmt.2008.03.005
Bashey A, Zhang X, Sizemore CA, et al. T‐cell‐replete HLA‐haploidentical hematopoietic transplantation for hematologic malignancies using post‐transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA‐matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310‐1316. doi:10.1200/JCO.2012.44.3523
Kasamon YL, Bolaños‐Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA‐haploidentical blood or marrow transplantation with high‐dose post‐transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33:3152‐3161. doi:10.1200/JCO.2014.60.4777
Solomon SR, Sizemore CA, Sanacore M, et al. Total body irradiation‐based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015;21:1299‐1307. doi:10.1016/j.bbmt.2015.03.003
Devillier R, Granata A, Fürst S, et al. Low incidence of chronic GVHD after HLA‐haploidentical peripheral blood stem cell transplantation with post‐transplantation cyclophosphamide in older patients. Br J Haematol. 2017;176(1):132‐135. doi:10.1111/bjh.13923
Cauchois R, Castagna L, Pagliardini T, et al. Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells. Br J Haematol. 2019;185(3):570‐573. doi:10.1111/bjh.15544
Pagliardini T, Castagna L, Harbi S, et al. Thiotepa, fludarabine, and busulfan conditioning regimen before T cell‐replete haploidentical transplantation with post‐transplant cyclophosphamide for acute myeloid leukemia: a bicentric experience of 100 patients. Biol Blood Marrow Transplant. 2019;25(9):1803‐1809. doi:10.1016/j.bbmt.2019.05.014
Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA‐mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282‐288. doi:10.1182/blood‐2011‐03‐344853
McCurdy SR, Kanakry JA, Showel MM, et al. Risk‐stratified outcomes of nonmyeloablative HLA‐haploidentical BMT with high‐dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024‐3031. doi:10.1182/blood‐2015‐01‐623991
Ruggeri A, Labopin M, Bacigalupo A, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer. 2018;124(7):1428‐1437. doi:10.1002/cncr.31228
Bashey A, Zhang MJ, McCurdy SR, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow As a graft source for T‐cell‐replete haploidentical donor transplantation using post‐transplant cyclophosphamide. J Clin Oncol. 2017;35(26):3002‐3009. doi:10.1200/JCO.2017.72.8428
Mehta RS, Saliba RM, Alsfeld LC, et al. Bone marrow versus peripheral blood grafts for haploidentical hematopoietic cell transplantation with post‐transplantation cyclophosphamide. Transplant Cell Ther. 2021;27(12):1003.e1‐1003.e13. doi:10.1016/j.jtct.2021.09.003
Solomon SR, St Martin A, Shah NN, et al. Myeloablative vs reduced intensity T‐cell‐replete haploidentical transplantation for hematologic malignancy. Blood Adv. 2019;3(19):2836‐2844. doi:10.1182/bloodadvances.2019000627
Devillier R, Galimard JE, Labopin M, et al. Reduced intensity versus non‐myeloablative conditioning regimen for haploidentical transplantation and post‐transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2022;57(9):1421‐1427. doi:10.1038/s41409‐022‐01674‐x
Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry‐based studies in hematopoietic cell transplantation. Clin Hematol Int. 2020;2(1):2‐4. doi:10.2991/chi.d.191207.001
Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457‐481.
Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541‐554.
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377. doi:10.1182/blood.2022016867
O'Donnell PV, Eapen M, Horowitz MM, et al. Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non‐ablative conditioning: a matched‐pair analysis. Bone Marrow Transplant. 2016;51(12):1599‐1601. doi:10.1038/bmt.2016.215
Bradstock K, Bilmon I, Kwan J, et al. Influence of stem cell source on outcomes of allogeneic reduced‐intensity conditioning therapy transplants using haploidentical related donors. Biol Blood Marrow Transplant. 2015;21(9):1641‐1645. doi:10.1016/j.bbmt.2015.06.006
Sharma N, Faisal MS, Zhao Q, et al. Outcomes of bone marrow compared to peripheral blood for haploidentical transplantation. J Clin med. 2021;10(13):2843. doi:10.3390/jcm10132843
Mariotti J, Devillier R, Bramanti S, et al. Peripheral blood stem cells versus bone marrow for T cell‐replete haploidentical transplantation with post‐transplant cyclophosphamide in Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25(9):1810‐1817. doi:10.1016/j.bbmt.2019.05.017
Castagna L, Crocchiolo R, Furst S, et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post‐transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2014;20(5):724‐729. doi:10.1016/j.bbmt.2014.02.001
Nagler A, Dholaria B, Labopin M, et al. Bone marrow versus mobilized peripheral blood stem cell graft in T‐cell‐replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia. 2020;34(10):2766‐2775. doi:10.1038/s41375‐020‐0850‐9
Bazarbachi A, Boumendil A, Finel H, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma ‐ a LWP‐EBMT study. Br J Haematol. 2020;188(5):745‐756. doi:10.1111/bjh.16182
Devine SM, Owzar K, Blum W, et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced‐intensity conditioning regimen: results from cancer and leukemia group B 100103 (Alliance for clinical trials in oncology)/blood and marrow transplant clinical trial network 0502. J Clin Oncol. 2015;33(35):4167‐4175. doi:10.1200/JCO.2015.62.7273
Blaise D, Devillier R, Lecoroller‐Sorriano AG, et al. Low non‐relapse mortality and long‐term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. Haematologica. 2015;100(2):269‐274. doi:10.3324/haematol.2014.113571
Muffly L, Pasquini MC, Martens M, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130(9):1156‐1164. doi:10.1182/blood‐2017‐03‐772368